In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies. [Read more…]
CAR-T Financing Frenzy: $100 Billion in Market Cap by CAR-T Companies
CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. [Read more…]
Dr. Robert Hariri – Placental Pioneer Launches Celularity with $250M Cash
Dr. Robert Hariri is a fascinating figure in the stem cell industry, because he was the earliest pioneer to recognize the regenerative potential of the human placenta. In August 2017, Hariri brought his latest company, Celularity, into the spotlight by announcing a successful Series A financing with contributions from influential investors, including United Therapeutics Corporation, Celgene, Sorrento Therapeutics, and Human Longevity, Inc. (HLI).
Today, Celularity’s investor contributions have reached an astounding $250 million, including contributions from the Genting Group, Dreyfus Family Office and Tony Robbins, among other notable investors. [Read more…]
Ushering in the Era of CAR-T: Kymriah, Yescarta, and Tecartus
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” [Read more…]
Fate Therapeutics Gets FDA Clearance of IND Application for World’s First iPSC-derived CAR T-Cell Therapy
FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus
Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas
SAN DIEGO, July 09, 2020 — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.
FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 13
- Next Page »